Auro laboratories has filed its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory compliance document to BSE Limited on April 14, 2026, confirming proper handling of dematerialization activities during Q4FY26.

Regulatory Compliance Certificate

The certificate, signed by Whole Time Director Siddhartha Deorah, confirms that all details of securities dematerialized and rematerialized during the quarter have been furnished to stock exchanges where the company's shares are listed. This quarterly filing ensures compliance with SEBI's depositories regulations and maintains transparency in share transfer operations.

Registrar Confirmation

Purva Sharegistry (India) Private Limited, the company's registrar and transfer agent, provided supporting confirmation dated April 01, 2026. The registrar certified that:

• Securities received for dematerialization were confirmed to depositories within prescribed timelines
• Physical certificates were mutilated and cancelled after due verification
• Depository names were substituted in member registers as registered owners
• All securities are listed on stock exchanges where earlier issued securities are traded

Dematerialization Activity Summary

During Q4FY26, significant dematerialization activity occurred across multiple shareholders. The detailed records show systematic conversion of physical shares to electronic form throughout the quarter.

Notable Shareholder Activity

The dematerialization records reveal substantial activity from several shareholders. Key participants included:

• Gowri Jeyaraman: 20 certificates (2,000 shares) processed on February 03, 2026
• Ajai Saran: 24 certificates (2,400 shares) processed on February 13, 2026
• Manik Chaudhury: 10 certificates (1,000 shares) processed on February 25, 2026
• Kailash Chand Makipuria: 10 certificates (1,000 shares) processed on March 28, 2026

Monthly Distribution

The dematerialization activity was distributed across the quarter with consistent processing:

This quarterly filing demonstrates the company's commitment to regulatory compliance and facilitates investor preference for electronic share holding. The systematic processing of dematerialization requests reflects efficient coordination between the company, its registrar, and depository participants.

Auro Laboratories Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, demonstrating exceptional growth across all key performance indicators. The pharmaceutical company's Board of Directors approved these results during their meeting held on February 5, 2026.

Outstanding Quarterly Performance

The company delivered remarkable financial performance in Q3FY26, with revenue from operations reaching ₹939.30 lakhs compared to ₹306.47 lakhs in Q3FY25, marking an impressive 206% year-on-year growth. This substantial increase reflects the company's strengthened market position and operational efficiency.

Profitability Surge

Net profit for Q3FY26 soared to ₹195.18 lakhs from ₹5.10 lakhs in the corresponding quarter of the previous year, representing an extraordinary growth of 3,727%. The profit before tax stood at ₹173.84 lakhs compared to ₹6.81 lakhs in Q3FY25. Basic earnings per share improved significantly to ₹3.13 from ₹0.08 in the previous year quarter.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, Auro Laboratories maintained its strong momentum with revenue from operations of ₹2,090.56 lakhs against ₹1,185.82 lakhs in the corresponding period of FY25. Net profit for the nine-month period reached ₹266.18 lakhs compared to ₹116.17 lakhs in the previous year.

Operational Efficiency and Cost Management

The company demonstrated improved operational efficiency with total expenses of ₹783.16 lakhs in Q3FY26 compared to ₹312.75 lakhs in Q3FY25. Notable changes in inventory management contributed positively, with changes in inventories showing a favorable impact of ₹199.74 lakhs compared to an adverse impact of ₹110.38 lakhs in the previous year quarter.

Comprehensive Income and Capital Structure

Total comprehensive income for Q3FY26 stood at ₹179.95 lakhs compared to ₹8.88 lakhs in Q3FY25. The company maintains a stable capital structure with paid-up equity share capital of ₹623.25 lakhs, consisting of equity shares with a face value of ₹10 each. Other equity as of March 31, 2025, was ₹3,673.56 lakhs.

Regulatory Compliance and Audit

The unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and reviewed by the Audit Committee before Board approval. B.L. Dasharda & Associates, the company's statutory auditors, conducted a limited review of these results as per Regulation 33 of SEBI (LODR) Regulations, 2015. The company operates in a single segment of pharmaceuticals and has made appropriate provisions for gratuity in accordance with new Labour Codes implemented from November 21, 2025.